首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >Academic Drug Development: The DRIVE Model
【2h】

Academic Drug Development: The DRIVE Model

机译:学术药物开发:DRIVE模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although there are hundreds of academic drug discovery centers open around the world, there are comparatively few academic drug development centers that contain the key core competencies needed to progress a lead compound into clinical trials. This is largely a consequence of operating in the “Valley of Death” (i.e., insufficient infrastructure, expertise, and funding). We have created an academic drug development center called DRIVE (Drug Innovation Ventures at Emory) that was designed to overcome many of the intrinsic and occasionally unintended barriers associated with academic drug development. Herein, we report a proof of concept that the DRIVE model provides a robust framework for pursuing university-based drug development, especially when the drugs in question target rare and neglected diseases.
机译:尽管全球有数百家学术药物发现中心开放,但相对而言,具有将先导化合物进行临床试验所需的关键核心能力的学术药物开发中心相对较少。这很大程度上是在“死亡之谷”中运营的结果(即基础设施,专业知识和资金不足)。我们已经建立了一个学术药物开发中心,称为DRIVE(埃默里的药物创新风险投资公司),旨在克服许多与学术药物开发相关的内在和偶发性意外障碍。本文中,我们报告了一种概念验证,即DRIVE模型为追求基于大学的药物开发提供了强大的框架,特别是当所讨论的药物针对稀有和被忽视的疾病时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号